The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Beta-blockers in cirrhosis: Evidence-based indications and limitations
Open accessAbstract
Non-selective beta-blockers (NSBBs) are the mainstay of treatment for portal hypertension in the setting of liver cirrhosis. Randomised controlled trials demonstrated their efficacy in preventing initial variceal bleeding and subsequent rebleeding. Recent evidence indicates that NSBBs could prevent liver decompensation in patients with compensated cirrhosis. Despite solid data favouring NSBB use in cirrhosis, some studies have highlighted relevant safety issues in patients with end-stage liver disease, particularly with refractory ascites and infection. This review summarises the evidence supporting current recommendations and restrictions of NSBB use in patients with cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ripoll, C., Groszmann, R., Garcia–Tsao, G., Grace, N., Burroughs, A., Planas, R., Escorsell, A., Garcia–Pagan, J. C., Makuch, R., Patch, D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.024 · Cited by 1,183 · cited 2×
“Previous trials illustrated that decompensation risk was concentrated almost exclusively in patients with a baseline HVPG >−10 mmHg, the threshold defining CSPH.52 Moreover, patients with CSPH exhibit a greater HVPG response to NSBBs than those without, suggesting that NSBBs may be an effective option to prevent decom…”
BackgroundSelf-citationVillanueva, C., Albillos, A., Genescà, J., Garcia-Pagan, J. C., Calleja, J. L., Aracil, C., Bañares, R., Morillas, R. M., Poca, M., Peñas, B., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31875-0 · Cited by 711
Self-citationMookerjee, R. P., Pavesi, M., Thomsen, K. L., Mehta, G., Macnaughtan, J., Bendtsen, F., Coenraad, M., Sperl, J., Gines, P., Moreau, R., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.018 · Cited by 248 · cited 12×
“Regarding studies including carvedilol, Leithead et al. evaluated 322 patients with ascites listed for liver transplantation and found a significantly lower waitlist mortality in NSBB users.42 The subgroup of patients receiving carvedilol (median dose 6.25 mg/d) had a mortality risk between those on propranolol and th…”
ResultInfluentialβ‐Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta‐analysis
Senzolo, M., Cholongitas, E., Burra, P., Leandro, G., Thalheimer, U., Patch, D., & Burroughs, A. K. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02038.x · Cited by 241
Cited by
EASL Clinical Practice Guidelines on acute-on-chronic liver failure
Moreau, R., Tonon, M., Krag, A., Angeli, P., Berenguer, M., Berzigotti, A., Fernandez, J., Francoz, C., Gustot, T., Jalan, R., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.021 · Cited by 375
Kietaibl, S., Ahmed, A., Afshari, A., Albaladejo, P., Aldecoa, C., Barauskas, G., De Robertis, E., Faraoni, D., Filipescu, D. C., Fries, D., et al. (2023) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000001803 · Cited by 345
The role of matrix metalloproteinases in liver function and disease
Mitropoulou, G., Kompoura, V., Saffioti, F., & Mavroeidis, V. K. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl27127 · Cited by 14
Metadata
- Authors
- Rodrigues, S. G., Mendoza, Y. P., & Bosch, J.
- Venue
- JHEP Reports
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 2
- Issue
- 1
- Pages
- 100063
- ISSN
- 2589-5559 (ISSN-L)
- OpenAlex
- W2995510644
- Cited by
- 168
- References
- 4
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beta-blockers in cirrhosis: Evidence-based indications and limitations. https://app.cochat.ai/papers/10.1016/j.jhepr.2019.12.001
- The paper
- Rodrigues, S. G., Mendoza, Y. P., & Bosch, J. (2020). Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Reports. https://doi.org/10.1016/j.jhepr.2019.12.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.